Cancer intelligence company, C2i Genomics announced it has raised $100M in financing from Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital, and others.
– Funds will be used to accelerate clinical development and commercialization of the company’s C2-Intelligence Platform, a cancer diagnostics service, that uses AI pattern recognition and whole-genome analysis to provide rapid and cancer-specific detection of residual disease 100x more sensitive than legacy platforms.
– C2i Genomics also plans to use financing to strengthen partnerships with pharmaceutical companies and accelerate the development of novel oncology drugs and pursue regulatory and reimbursement approvals in the US and Europe.
– C2i Genomics received its $12M Series A round of funding in June 2020.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
C2i Genomics, is an AI and genomics startup, founded in 2019 and led by executives from Bristol-Myers Squibb, GSK, Tempus, Foundation Medicine, and Thrive Earlier Detection. The cloud-based platform was created to help labs provide deeper insights and subtle changes in cancer burden, and gives patients and physicians alike more precise knowledge of next steps or better treatment plans after tumor removal, i.e additional growth, shrinkage, or total elimination.